Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments
Open accessAbstract
BACKGROUND: Unlike cytotoxic agents, novel antineoplastic drugs can variably affect thyroid function and so impair patient outcomes. However, the widely used standard thyroid tests have demonstrated low sensitivity for detecting early thyroid damage that leads to dysfunction of the gland. To find a more reliable thyroid marker, we assessed the presence of antibodies binding thyroid hormones (thAbs) in a cancer population undergoing potentially thyrotoxic treatment. METHODS: From April 2010 to September 2013, 82 patients with hematologic malignancies treated with tyrosine kinase inhibitors or immunoregulatory drugs were recruited. Healthy volunteers (n = 104) served as control subjects. Thyroid function, autoimmunity tests, thAbs, and thyroid sonography were assessed once during treatment. RESULTS: Overall, thAb positivity was recorded in 13% of the entire cohort. In most cases, the thAbs were of a single type, with a predominance of T3 immunoglobulin G. More specifically, thAbs were detected in 11 cancer patients; and abnormal levels of thyroid-stimulating hormone, thyroglobulin antibody, and thyroperoxidase antibody were detected in 6 (p = 0.05), 0 (p = 0.0006), and 2 cancer patients (p = 0.001) respectively. Ultrasonographic alterations of the thyroid were observed in 12 cancer patients. In contrast, of the 104 healthy control subjects, only 1 was positive for thAbs (1%). CONCLUSIONS: We have demonstrated for the first time that thAbs are a reliable marker of early thyroid dysfunction when compared with the widely used standard thyroid tests. A confirmatory prospective trial aiming at evaluating thAbs at various time points during treatment could clarify the incidence and timing of antibody appearance.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Thyroid hormone autoantibodies appeared in 14% of thalidomide or lenalidomide-treated patients.
“Interestingly, thyroid hormone autoantibodies appeared in 14% of thalidomide or lenalidomide-treated patients (61).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Thyroid Dysfunction from Antineoplastic Agents
Hamnvik, O. R., Larsen, P. R., & Marqusee, E. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr373 · Cited by 165 · see citing works
Ruggeri, R. M., Galletti, M. R., Mandolfino, M. G., et al. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03344036 · Cited by 53 · see citing works
Self-citationBenvenga, S., Burek, C. L., Talor, M. V., et al. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03344071 · Cited by 42 · see citing works
Self-citationThyroid Hormone Autoantibodies Elicited by Diagnostic Fine Needle Biopsy1
Benvenga, S., Bartolone, L., Squadrito, S., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4420 · Cited by 41 · see citing works
Self-citationTrimarchi, F., Benvenga, S., Costante, G., et al. (1983) · Journal of Endocrinological Investigation · doi:10.1007/bf03350609 · Cited by 39 · see citing works
Self-citationThyroid Hormone Autoantibodies Elicited by Diagnostic Fine Needle Biopsy
Benvenga, S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4217 · Cited by 34 · see citing works
Self-citationRe: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Garfield, D., Hercbergs, A. A., & Davis, P. J. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm008 · Cited by 25 · see citing works
Spontaneous thyroiditis in the obese strain of chickens. VI. Thyroxine-binding antibodies.
Nilsson, L. A., Rose, N. R., & Witebsky, E. (1971) · PubMed · Cited by 20 · see citing works
Sunitinib-induced myxedema coma
Chen, S., Kao, P.-C., Lin, Z., Chiang, W., & Fang, C. (2009) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2008.07.012 · Cited by 19 · see citing works
Increasing frequency and clinical significance of thyroid hormone autoantibodies
Benvenga, S., & Trimarchi, F. (2004) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000137759.57791.f8 · Cited by 18 · see citing works
Self-citationCell-surface receptor for thyroid hormone and tumor cell proliferation
Davis, P. J., Davis, F. B., Lin, H., Bergh, J. J., Mousa, S. A., Hercbergs, A. A., Fenstermaker, R. A., & Ciesielski, M. J. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.6.753 · Cited by 16 · see citing works
Models to study the pathogenesis of thyroid autoimmunity
Rasmussen, Å. K., Hartoft‐Nielsen, M., & Feldt‐Rasmussen, U. (1999) · Biochimie · doi:10.1016/s0300-9084(99)80103-5 · Cited by 11 · see citing works
Thyroid function, autoimmunity and nodules in hematological malignancies
Mondello, P., Sindoni, A., Pitini, V. V., Scisca, C., Altavilla, G., & Benvenga, S. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000044 · Cited by 10 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunc- tion from antineoplastic agents. J Natl Cancer Inst 2011; 103:1572-87.
Cited by
Sorted by citations
L-T4 therapy in the presence of pharmacological interferents
Benvenga, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.607446 · Cited by 13 · see citing works
“Interestingly, thyroid hormone autoantibodies appeared in 14% of thalidomide or lenalidomide-treated patients (61).”
BackgroundSelf-citation
- Authors
- Mondello, P., Mian, M., Pitini, V., Cuzzocrea, S., Sindoni, A., Galletti, M., Mandolfino, M., Santoro, D., Mondello, S., Aloisi, C., Altavilla, G., & Benvenga, S.
- Affiliations
- University of Messina (IT)
- Ospedale di Bolzano (IT)
- Corresponding author
- Mondello, P.
- Venue
- Current Oncology
- Publisher
- MDPI AG
- Published
- 2016-06-01
- Volume
- 23
- Issue
- 3
- Pages
- 165-170
- ISSN
- 1198-0052 (ISSN-L)
- 1718-7729
- PMC
- PMC4900836
- OpenAlex
- W2433579966
- Cited by
- 11
- References
- 13
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 4 · 2018: 1 · 2017: 2
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Current Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- hematologic malignancies, tyrosine kinase inhibitors, immunotherapy, drug-induced thyroid dysfunction, thyroglobulin antibodies, thyroid peroxidase antibodies, thyroid ultrasound, antineoplastic drug toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
